The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis

详细信息	查看全文 | 推荐本文 |

• 作者：Yasunori Uemura ; Hiroaki Ohno ; Yumiko Ohzeki ; Hiromi Takanashi ; Hideko Murooka ; Kazuo Kubo ; Isao Serizawa
• 关键词：Ki20227 ; M-CSF ; c-fms ; Myeloid cells ; Experimental autoimmune encephalomyelitis
• 刊名：Journal of Neuroimmunology
• 出版年：2008
• 期刊代码：32_01655728
• 类别：neu
• 出版时间：March 2008
• 卷：195
• 期：1-2
• 页码：73-80
• 文件大小：605 K

摘要

Experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), can be induced by the immunization of mice with myelin antigens in the form of myelin oligodendrocyte glycoprotein (MOG). Macrophage colony-stimulating factor (M-CSF) is required for the development of individual mononuclear phagocyte populations and is involved in the immune response. We previously reported that Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl]urea) is a highly selective M-CSF receptor (c-fms) tyrosine kinase inhibitor. In our current study, we investigated whether Ki20227 has suppressive effects upon EAE and indeed found that this drug significantly reduced the severity of this disease both preventively and therapeutically. Notably also, Ki20227 treatments inhibited the turn-over/expansion of myeloid cells provoked by the immunization and subsequent MOG-specific T cell responses in our EAE animal model. These findings suggest that M-CSF plays a pivotal role in the development of EAE and that Ki20227 and its derivatives may be candidate drugs for the treatment of human MS.